Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

Valneva Reports Full Year 2023 Revenue and Cash,
Provides First 2024 Guidance

Total revenues of €153.7 million, including product sales of €144.6 million

• Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26%
• Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022

Cash position of €126.1 million at December 31, 2023

• Excludes recent sale of the Priority Review Voucher (PRV) for $103 million (€95 million)¹                                                                                                                                                                                                                                                                                                                                          
• Reflects significant payments related to the Phase 3 Lyme disease study, for which Valneva’s cost contributions are expected to be completed in the first half 2024²

First full year 2024 guidance